

1 **Long Title:** A Randomized Controlled Double-Blinded Split-Face Prospective Clinical  
2 Trial to Assess the Efficacy, Safety, and Tolerability of a Novel 3-Step Routine  
3 Compared to Benzyl Peroxide for the Treatment of Mild to Moderate Acne Vulgaris  
4

5 Short Title: Geologie Clear System versus a BPO Routine for Acne  
6

7 Authors: Alison Gern,<sup>1</sup> Jessica Walter MD FACOG,<sup>2</sup> Shuai Xu MD FAAD,<sup>1,3,4\*</sup> and Paras  
8 P. Vakharia MD PharmD<sup>1</sup>  
9

10 1. Department of Dermatology - Northwestern University Feinberg School of Medicine  
11 (Chicago, IL)

12 2. Department of Obstetrics and Gynecology – Northwestern University Feinberg  
13 School of Medicine (Chicago, IL)

14 3. Department of Pediatrics (Dermatology) - Northwestern University Feinberg School of  
15 Medicine (Chicago, IL)

16 4. Sibel Health Inc. (Chicago, IL)  
17

18 Corresponding Author: Shuai Xu MD (steveux@northwestern.edu).  
19

20 Ethical statement: SX has stock options and is a consultant of Regimen - the  
21 manufacturer of one of the products studied here. JRW has a spouse with stock options  
22 and a consultant of Regimen – the manufacturer of one of the products studied here.  
23

24 Funders: Regimen  
25

26 Statement contribution: AG collected data, analyzed data, and generated figures. SR  
27 oversaw data collection, IRB approval, and study conduct. SX wrote manuscript and  
28 analyzed results. JRW performed statistical analysis and provided critical revisions of  
29 the manuscript. PV supported data collection, made critical edits to the manuscript, and  
30 scored all raw data outputs.  
31

32 Acknowledgements: None  
33

34 **Abstract**

35

36 Adult acne vulgaris affects up to 43-51% of individuals. While there are numerous  
37 treatment options for acne including topical, oral, and energy-based approaches,  
38 benzoyl peroxide (BPO) is a popular over the counter (OTC) treatment. Although BPO  
39 monotherapy has a long history of efficacy and safety, it suffers from several  
40 disadvantages, most notably, skin irritation, particularly for treatment naïve patients. In  
41 this prospective, randomized, controlled, split-face study, we evaluated the comparative  
42 efficacy, safety, and tolerability of a novel 3-step azelaic acid, salicylic acid and  
43 graduated retinol regimen (Geologie Clear System) versus a common OTC BPO-based  
44 regimen (Proactiv Solution) over 12 weeks. A total of 37 adult subjects with self-  
45 reported mild to moderate acne vulgaris were recruited. A total of 21 subjects  
46 underwent a 2-week washout period and completed the full study with 3 dropping out  
47 due to product irritation from the BPO routine, and 13 being lost to follow-up. Detailed  
48 tolerability surveys were conducted at Week 4. Additional surveys on tolerability and  
49 product preferences were collected monthly, at Week 4, Week 8, and Week 12. A  
50 blinded board-certified dermatologist objectively scored the presence and type of acne  
51 lesions (open or closed comedones, papules, pustules, nodules, and cysts) at baseline,  
52 Week 4, Week 8, and Week 12. Patients photographed themselves and uploaded the  
53 images using personal mobile phones. Detailed Week 4 survey results showed across  
54 25 domains of user-assessed product performance, Geologie outperformed the BPO  
55 routine in 19 (76%) which included domains in preference (e.g. “I would use this in the  
56 future), performance (“my skin improved” and “helped my acne clear up faster”).  
57 Geologie users reported less facial redness, itching, and burning, though differences did  
58 not reach statistical significance. In terms of efficacy, both products performed similarly,  
59 reducing total acne lesions by 36% (Geologie) and 40% (BPO routine) by Week 12.  
60 Overall, accounting for user preferences and tolerability Geologie was more preferred  
61 than the BPO routine in 79% of domains (22/28). Differences in objective acne lesion  
62 reduction were not statistically significant ( $p=0.97$ ). In a randomized split-face study, a  
63 3-step azelaic acid, salicylic acid, and graduated retinol regimen delivered similar acne  
64 lesion reduction, fewer user dropouts, greater user tolerability, and higher use  
65 preference compared to a 3-step BPO routine based in a cohort of participants with  
66 mild-to-moderate acne vulgaris.

67

68 **Introduction**

69  
70 Acne vulgaris is one of the most common human diseases in adults affecting 43-51% of  
71 individuals between the ages of 20 to 29 and up to 35% of individuals between the ages  
72 of 30 to 39.<sup>1</sup> The disease can be disfiguring with a profound psychological impact,  
73 contributing to both anxiety and depression.<sup>2</sup> Currently, there are a wide range of  
74 topical, oral, and energy-based therapies for acne. Topical, over-the-counter (OTC)  
75 therapies are popular, representing a global \$5 billion USD market.<sup>3</sup> Within this category  
76 of topical treatments, benzoyl-peroxide (BPO) based therapies remain one of the most  
77 commonly used worldwide.

78  
79 While BPO as a monotherapy is an effective treatment for acne,<sup>4</sup> it has significant side  
80 effects that affect adherence, including skin irritation and patient intolerability,  
81 particularly among individuals with sensitive skin. In one study, 35% of BPO users noted  
82 side effects with a discontinuation rate of 44% at 6 months.<sup>5</sup> Importantly, the prevalence  
83 of sensitive skin in the adult population is greater than 70% in a recent systematic  
84 review.<sup>6</sup> Thus, new OTC regimens offering comparable efficacy with greater tolerability  
85 compared to existing BPO therapies would be beneficial to adult patients with mild-to-  
86 moderate acne vulgaris.

87  
88 We hypothesized a novel 3-step regimen with 3 primary anti-acne ingredients (azelaic  
89 acid, salicylic acid, and retinol) would offer similar efficacy and greater tolerability  
90 compared to a popular 3-step BPO based product in adult patients with mild-to-  
91 moderate acne vulgaris. Therefore, we conducted a randomized controlled split-face  
92 study to investigate the efficacy, safety, and tolerability of both OTC regimens.

93  
94 **Materials and Methods**

95 *Regimens*

96 Two OTC regimens were compared. The first OTC regimen (Geologie, New York City,  
97 New York) included 3 separate products: 1) a cleanser (2% salicylic acid), 2) a day  
98 cream (5% azelaic acid, 2% hyaluronic acid, and 1% niacinamide), and 3) a night cream  
99 with graduated levels of retinol to maximize patient tolerability. From baseline to week 4,  
100 subjects were given a night cream with 0.1% retinol. From week 4 to week 8, subjects  
101 were given a night cream with 0.2% retinol. Finally, from week 8 to week 12, subjects  
102 were given a night cream with 0.3% retinol. The second OTC Regimen (Proactiv  
103 Solution, Southaven, Mississippi) also included 3 separate products: 1) a cleanser  
104 (2.5% BPO), 2) a toner (glycolic acid), and 3) repairing treatment (2.5% BPO). Proactiv  
105 Solution was selected given its high level of popularity as a BPO routine, and a similar  
106 3-step routine as the Geologie Clear System. All products from each OTC regimen were  
107 transferred to unlabeled bottles to maximize blinding. Instructions on applications and  
108 use were provided per each manufacturers' instructions. The dermatologist performing  
109 skin lesion grading was blinded to treatment laterality.

110  
111 *Study Design, Enrollment, Inclusion / Exclusion Criteria, and Study Endpoints*

112 This was a prospective, randomized controlled, double-blinded, single-center study  
113 (clinicaltrials.gov: NCT05446402) conducted at Northwestern University in the

114 Department of Dermatology after IRB approval (STU00217056). Patients were recruited  
115 in person and via social media (e.g., Facebook). A split-face design was used to  
116 compare the Geologie Clear System versus the BPO routine. All eligible subjects (>18  
117 years of age with a clinical diagnosis of mild or moderate acne vulgaris and without an  
118 active skin infection or known allergy to the ingredients being evaluated) were recruited  
119 and consented. Acne lesion count (open comedones, closed comedones, papules,  
120 pustules, nodules, and cysts) was determined by a blinded board-certified dermatologist  
121 (PV) at baseline, Week 4, Week 8, and Week 12 of the study via the Facial Lesion  
122 Count.<sup>7</sup> Patients self-collected images with standard mobile phones. Subjects were  
123 asked to complete both tolerance and product preference surveys at Week 4, Week 8,  
124 and Week 12. For tolerability, subjects were asked to rate their level of redness, itching,  
125 and burning on a 5-point scale with 1 being very mild and 5 being very severe. For  
126 patient preferences, subjects were asked to complete questions related to the product's  
127 effect on their skin, and their propensity to use the product in the future on a 5-point  
128 scale. The primary endpoint was acne lesion count with secondary endpoints including  
129 both patient preference and tolerability survey results.

130

131 As a non-inferiority study, 20 subjects would enable the detection of an absolute  
132 difference of 20% with at least 80% power and a 5% level of significance if the standard  
133 deviation of this difference is no larger than 50%. Adjusting for a drop rate of 25%, a  
134 target of 27 subjects for recruitment and consent was set. The data were analyzed  
135 using Stata. Aggregated data for lesion counts were determined for each time point  
136 during the study (baseline, Weeks 4, 8, and 12 of treatment use). Descriptive statistics  
137 are presented as means. Paired t-tests were used to compare performance with all p-  
138 values were two-tailed assuming equal variances with a level of significant of  $p \leq 0.05$ .

139

## 140 **Results**

141 A total of 37 subjects were recruited and consented for the 12-week study. Expansion of  
142 the initial target recruitment was required due to drop out of three subjects due to  
143 intolerance of the BPO routine and a higher than anticipated lost-to-follow up rate  
144 ( $n=13$ ) (Figure 1). Prior to starting both regimens, the final cohort of patients ( $n=21$ )  
145 completed a 2-week washout period where no acne treatments, prescription, or OTC  
146 medications were used. The final analysis cohort included 10 females, 10 males, and 1  
147 not reported (Table 1). Most subjects were between the ages of 20-29 ( $n=10$ ) and 30-39  
148 ( $n=6$ ). Self-reported skin type was most reported as a combination of oily and dry (61%;  
149  $n=13/21$ )

150

151 Both Geologie and the BPO routine demonstrated a high degree of efficacy evidenced  
152 by reduction in facial lesions. At week 4, both regimens had a similar mean number of  
153 acne lesions (Geologie: 7.2 and Proactiv: 7.5) with no statistical difference ( $p=0.80$ ). At  
154 week 8, Geologie had an average of 6.6 acne lesions and the BPO routine had an  
155 average of 6.5 acne lesions ( $p=0.94$ ). At week 12, Geologie had an average of 4.6 acne  
156 lesions and the BPO routine had an average of 4.7 acne lesions ( $p=0.93$ ). Over the  
157 entire 12 weeks, each product reduced total acne lesions by 36% (Geologie Clear  
158 System) and 40% (BPO routine).

159

160 Detailed patient preference and user tolerability in Week 4 are shown in Figure 2.  
161 Across a total of 25 domains, the Geologie Clear System outperformed the BPO routine  
162 in 19 domains (76%). Geologie’s highest performing categories were a patient’s  
163 likelihood to use the product in the future, skin feel, and preference. In addition, the  
164 Geologie Clear System was preferred in domains for efficacy (faster acne clearing, skin  
165 less oily) and skin look and feel (softer, smoother, brighter, and more hydrated). The  
166 BPO routine was favored in other categories related to acne prevention. When  
167 aggregating both user preferences and tolerability Geologie was more preferred than  
168 the BPO routine in 79% of domains (22/28) at Week 4. In Figure 3, users reported  
169 higher scores for the Geologie Clear System in skin feel, and future product usage at  
170 Week 4 and Week 8. At Week 12, these differences were less apparent (Figure 3).  
171 Additional survey results on tolerability and product preferences were collected at Week  
172 4, Week 8, and Week 12. Detailed Week 4 survey results showed that across 25  
173 domains of user-assessed product performance, In terms of tolerability, Geologie users  
174 reported less facial redness, itching, burning, and dryness (Figure 4).

175

### 176 *Safety*

177 No adverse events were reported during this study, although three subjects dropped out  
178 due to intolerance to the BPO routine during the course of the 12-week study.

179

### 180 **Discussion**

181 The pathogenesis of acne vulgaris is multi-factorial driven by increased sebum  
182 production via hyperplastic sebaceous glands, bacterial colonization by *p. acnes*,  
183 follicular hyperkeratinization, and inflammation.<sup>8</sup> BPO based treatments have long been  
184 a cornerstone treatment for acne vulgaris given its ability to reduce antibacterial activity  
185 against *Cutibacterium acnes* and suppress sebum production.<sup>9</sup> However, skin irritation  
186 and tolerability remain a key drawback of BPO-based treatments, particularly at higher  
187 concentrations<sup>10</sup>—an issue likely exacerbated in the adult acne population with a high  
188 underlying prevalence of skin sensitivity. The Proactiv Solution 3-step regimen includes  
189 2 products with BPO and glycolic acid toner. For BPO, the predominate mechanism of  
190 action is antibacterial.<sup>11</sup> Glycolic acid has largely anti-hyperkeratinization activity.<sup>12</sup> The  
191 Geologie regimen was rationally designed to deliver comparable efficacy to BPO based  
192 treatments with greater tolerability and less irritation to maximize compliance—this is  
193 evident in that no participants dropped out of the study due to intolerance to the  
194 Geologie regimen compared to 3 subjects who dropped out due to the BPO routine.  
195 Azelaic acid, already FDA-cleared as a topical treatment for acne in a 20% cream  
196 formulation, offers multiple effect anti-acne benefits including being bactericidal for *C.*  
197 *acnes*, anti-inflammatory, and skin lightening for post-inflammatory hyperpigmentation.<sup>13</sup>  
198 Salicylic acid, a beta-hydroxy acid, has also long been a mainstay of acne treatments  
199 with a positive effect on abnormal keratinization, and inflammation. Niacinamide also  
200 address abnormal sebum production and anti-inflammatory activities. Retinols address  
201 hyper-keratinization, provide antibacterial action, and deliver color correction.<sup>12</sup> Given  
202 that retinols, like BPO, have well-established skin irritation and dryness side effects,  
203 particularly in treatment naïve or sensitive skin patients, the graduated retinol  
204 percentage process (0.1% at month 1, 0.2% month 2, and 0.3% at month 3) was  
205 designed to enhance patient tolerability without loss of efficacy. Combination therapies,

206 such as those offered by Geologie, have shown to offer better overall performance than  
207 monotherapy strategies.<sup>14</sup>

208  
209 The overall results show nearly identical efficacy in reducing objective acne lesion  
210 reduction at 12 weeks between both Geologie and the BPO routine. In contrast, and  
211 particularly at the Week 4 time point, the Geologie regimen exhibited higher ratings by  
212 user report across multiple domains from direct product preferences to skin appearance  
213 and skin feel. These differences were less apparent at Week 8 and Week 12, although  
214 Geologie was still rated higher in skin look and feel, and product perception at the end  
215 of the study. In regards to tolerability, Geologie demonstrated less severe redness,  
216 itching, and burning with the greatest differences seen at Week 4. These tolerability  
217 differences, analogous to the user preference reports, were less evident at Week 12.  
218 Overall, tolerability and user acceptance is critical in the management of acne, a chronic  
219 disease typically requiring on-going maintenance treatment. User tolerance is  
220 particularly relevant among adults with comorbid sensitive skin. Between 30% to 65% of  
221 all patients with acne do not adhere to a treatment regimen and as a result 50% do not  
222 receive the full benefits of treatment.<sup>15</sup> For OTC regimens, skin irritation and drying is  
223 the most common side effect.<sup>16</sup> To drive greater adherence and overall treatment  
224 success, products should be both effective and also tolerable to use.<sup>14,17</sup> These results  
225 suggest that positive early experiences by new users is especially important—the  
226 Geologie system performed better in 79% of user reported domains in efficacy, product  
227 performance, and tolerability at the critical 4 week mark. Though outside the scope of  
228 this study, early positive experiences may encourage continued and longer-term  
229 adherence to treatment reducing rates of drop out among new users and long term  
230 benefits in terms of acne reduction.

231  
232 There are some relevant limitations to note. While a randomized double-blind split-face  
233 design lowers the risk of confounders, the final analysis set included only 21 subjects.  
234 The high dropout rate where patients were lost to follow up may reduce the confidence  
235 in the overall results—we anticipate this to largely be due to high survey burden. Future  
236 work should expand on these initial findings in a larger cohort.

## 237 238 **Conclusion**

239  
240 A rationally designed 3-step regimen with azelaic acid, niacinamide, salicylic acid, and  
241 graduated nightly retinol resulted in comparable acne lesion reduction with higher  
242 overall patient tolerability and patient preferences compared to a 3-step regimen with  
243 BPO and glycolic acid in a randomized, double-blind, split-face study of 21 adult  
244 patients with acne vulgaris over 12 weeks of therapy.

245  
246  
247  
248  
249  
250  
251

252 **References**

253

- 254 1. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20  
255 years and older. *J Am Acad Dermatol*. 2008;58(1):56-59.
- 256 2. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and  
257 risk of depression and anxiety: A meta-analytic review. *J Am Acad Dermatol*.  
258 2020;83(2):532-541.
- 259 3. Insights FB. U.S. Acne Treatment Market Size, Share & COVID-19 Impact  
260 Analysis. [https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-](https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-106565)  
261 [106565](https://www.fortunebusinessinsights.com/u-s-acne-treatment-market-106565). Published 2023. Accessed October 10, 2023, 2023.
- 262 4. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new  
263 perspectives on formulation and utilization. *Dermatol Clin*. 2009;27(1):17-24.
- 264 5. Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and  
265 adherence rate. *J Int Med Res*. 2019;47(7):2987-2992.
- 266 6. Chen W, Dai R, Li L. The prevalence of self-declared sensitive skin: a systematic  
267 review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2020;34(8):1779-  
268 1788.
- 269 7. Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J. A  
270 multirater validation study to assess the reliability of acne lesion counting. *J Am*  
271 *Acad Dermatol*. 1996;35(4):559-565.
- 272 8. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. *Lancet*.  
273 2012;379(9813):361-372.
- 274 9. Fulton JE, Jr., Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of  
275 action to topical benzoyl peroxide and vitamin A acid in acne vulgaris. *J Cutan*  
276 *Pathol*. 1974;1(5):191-200.
- 277 10. Segransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current  
278 use in the treatment of acne vulgaris. *Expert Opin Pharmacother*.  
279 2009;10(15):2555-2562.
- 280 11. Matin T, Goodman MB. Benzoyl Peroxide. In: *StatPearls*. Treasure Island (FL)  
281 ineligible companies. Disclosure: Marcus Goodman declares no relevant financial  
282 relationships with ineligible companies.2023.
- 283 12. Araviiskaia E, Dreno B. The role of topical dermocosmetics in acne vulgaris. *J*  
284 *Eur Acad Dermatol Venereol*. 2016;30(6):926-935.
- 285 13. Schulte BC, Wu W, Rosen T. Azelaic Acid: Evidence-based Update on  
286 Mechanism of Action and Clinical Application. *J Drugs Dermatol*. 2015;14(9):964-  
287 968.
- 288 14. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a  
289 Global Alliance to Improve Outcomes in Acne. *J Am Acad Dermatol*. 2003;49(1  
290 Suppl):S1-37.
- 291 15. Thiboutot D, Dreno B, Layton A. Acne counseling to improve adherence. *Cutis*.  
292 2008;81(1):81-86.
- 293 16. Decker A, Graber EM. Over-the-counter Acne Treatments: A Review. *J Clin*  
294 *Aesthet Dermatol*. 2012;5(5):32-40.
- 295 17. Flanders PA, McNamara JR. Enhancing acne medication compliance: a  
296 comparison of strategies. *Behav Res Ther*. 1985;23(2):225-227.

297




Figure 1. Flow chart of recruitment and final analysis dataset.



<b>Demographics</b>	
Total	21
<b>Sex</b>	
Male	10
Female	10
Prefer Not to Say	1
<b>Age</b>	
20-29	10
30-39	6
40-49	2
Not Reported	3
<b>Skin Type</b>	
Dry	2
Normal	2
Combination	13
Oily	4
<b>Embarrassment from Skin</b>	
Very Much	1
A Lot	4
A Little	13
Not at All	3
<b>Ethnicity</b>	
Asian	5
Black	2
Hispanic or Latino	4
White	8
Other	2

Table 1. Final demographics of n=21 subjects with mild-to-moderate acne vulgaris.




Figure 2. Detailed tolerability and preference survey conducted at Week 4 showed greater preference for the Geologie product across the majority of domains.




Figure 3. Week 4, Week 8, and Week 12 preference survey comparing key domains for the Geologie routine versus the BPO routine.



Figure 4. Week 4, Week 8, and Week 12 tolerability survey comparing key domains for Geologie routine versus the BPO routine. Higher preferences were reported for Geologie in Week 4 compared to Week 8 and Week 12.

### Split Face Acne Lesion Count Reduction Per Patient: Week 4, Week 8, and Week 12




Figure 5. Week 4, Week 8, and Week 12 objective acne lesion (both inflammatory and non-inflammatory) counts for each regimen. There were no statistically significant differences at any week between the Geologie routine versus the BPO routine. The final reduction in objective acne lesions from baseline was 36% for Geologie and 40% for the BPO routine.